Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Randomized, Double Blind, Parallel Group, Placebo Controlled, Multi-centre, Multinational Study to Evaluate Efficacy and Safety of TRC150094 as an Add On to Standard of Care in Improving Cardiovascular Risk in Subjects With Diabetes, Dyslipidemia and Hypertension

NCT03254446 is registered in ClinicalTrials.gov with Torrent Pharmaceuticals Limited as lead sponsor.

NCT NCT03254446
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03254446 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Randomized, Double Blind, Parallel Group, Placebo Controlled, Multi-centre, Multinational Study to Evaluate Efficacy and Safety of TRC150094 as an Add On to Standard of Care in Improving Cardiovascular Risk in Subjects With Diabetes, Dyslipidemia and Hypertension
Lead sponsor
Torrent Pharmaceuticals Limited
Phase
Phase 3
Overall status
Unknown status
Start date
March 12, 2018
Completion date
August 31, 2022
Enrollment
1,250 (estimated)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes, dyslipidemias, hypertension